COVID-19 - Pipeline Analysis - Drug Development Strategies by Therapy, RoA, Target

1. Downloaded from: justpaste.it/97f3k COVID-19 - Pipeline Analysis - Drug Development Strategies This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc. Get Sample of the Report: https://www.technavio.com/talk-to-us?report=IRTNTR43345&type=sample&src=report Overview of Therapeutic Pipeline for COVID-19 The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally. Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy Monotherapy Combination therapy Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs. COVID-19 - Pipeline Analysis: Key Highlights of the Report

2. What are the therapy molecules used in the various development stages of COVID-19? What are the companies that are currently involved in the development of therapeutic molecules for COVID- 19? Insight into discontinued/inactive molecules with appropriate reasoning? What are the major regulatory authorities approving drugs in various regions? Detailed profiling of each active molecule